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ABSTRACT
Background. Despite recent advances in the therapy for
adenocarcinoma of the esophagogastric junction (AEG),
overall prognosis remains poor. Programmed cell death
protein 1 (PD1) is a co-inhibitory receptor primarily
expressed by T-cells. Tumor cells can escape anticancer
immune responses by triggering the PD1 pathway. More-
over, PD1 receptor engagement on cancer cells may trigger
tumor-intrinsic growth signals. This study aimed to eval-
uate the potential clinical relevance of PD1 expression by
tumor-infiltrating lymphocytes (TILs) and cancer cells in
the AEG.
Methods. Patients with AEG who underwent esophagec-
tomy from 1992 to 2011 were included in the study.
Expression of PD1was evaluated by immunohistochemistry
and correlated with long-term overall survival (OS), disease-
free survival (DFS), and various clinicopathologic
parameters.
Results. Tumor biospecimens from 168 patients were
analyzed. In the analysis, 81% of the patients showed high
tumoral frequencies ([5%) of PD1-expressing TILs (TIL-
PD1?), and 77% of patient tumors harbored high levels
([5%) of PD1? cancer cells (cancer-PD1?). Expression of
PD1 by TILs and cancer cells correlated significantly
(p\ 0.05) with patients’ tumor stage and lymph node
involvement. Compared with the patients who had low
tumoral frequencies of PD1? TILs or cancer cells, the TIL-
PD1? and cancer-PD1? patients demonstrated significantly
reduced DFS in the univariate analysis (5-year DFS: 73.3
vs. 41.9%, log-rank 0.008 and 71.3 vs. 41.6%, p = 0.008,
respectively). Additionally, the cancer-PD1? patients
showed significantly decreased OS in the univariate anal-
ysis compared with the cancer-PD1- patients (5-year OS:
68.8 vs. 43.5%; p = 0.047). However, these correlations
did not reach significance in the multivariate analysis.
Conclusions. The PD1 receptor is expressed by both TILs
and cancer cells in AEG. High expression of PD1 is
associated with advanced tumor stage and lymph node
involvement, but not with survival.
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Esophageal cancer is the eighth most common cancer
worldwide, with dramatically increasing prevalence, and
the sixth most common cause of cancer-related death.1
Besides surgical resection, therapeutic strategies include
radiotherapy, cytotoxic chemotherapy,2 and treatment with
the monoclonal antibody, trastuzumab, targeting human
epidermal growth factor receptor 2 (HER2), which is
overexpressed in about 1 5% of esophageal carcinomas.3
Despite these current therapies, overall survival (OS) rates
remain low, with 5-year survival percentages ranging from
approximately 10 to 15%.2 Accordingly, new molecular
targets are urgently needed to improve patient outcome.
Recently, the programmed cell death 1 (PD1) protein, an
immune checkpoint receptor primarily expressed by acti-
vated T-cells, has been described as a key mediator of
tumor immune evasion and cancer progression.4,5 Expres-
sion of the PD1 ligands PD-L1 and PD-L2 by tumor-
infiltrating lymphocytes (TILs) and cancer cells has been
described for various tumor entities including melanoma,
multiple myeloma, breast cancer, renal cell carcinoma,
colorectal cancer, and lung carcinoma.6 High expression of
PD1 ligands in the tumor microenvironment (TME) has
been associated with adverse clinical outcome 7,8 and
escape from tumor-specific T cell immunity via a process
termed adaptive immune resistance.9,10 Therapeutic PD1-
blocking antibodies have been developed to counteract this
prominent tumor immune escape mechanism. In clinical
trials, PD1 inhibitors have shown remarkable efficacy in
patients with advanced cancers of various etiologies
including melanoma, renal cell carcinoma, non-small cell
lung cancer, and colorectal carcinoma.11,12
In esophageal carcinoma, data regarding PD1 expression
in the TME is sparse, and little is known about the potential
significance of PD1 as a cancer therapeutic target and
mechanism of disease progression. A recent study by Chen
et al.13 showed PD1 surface protein expression by TILs in
33.5% and PD-L1 expression by TILs and/or cancer cells
in 41.4% of patients with esophageal squamous cell car-
cinoma. Tumoral PD-L1 expression levels correlated with
postoperative outcome, but no significant associations
between PD1 expression and clinicopathologic parameters
or postoperative outcome were determined in this patient
cohort. In contrast, a separate study involving gastric
cancer patients showed that PD1 expression by CD4? and
CD8? TILs correlated positively with tumor progression.14
In addition to the well-established role of PD1 in
dampening T-cell responses,10,15 recent evidence suggests
that the PD1 receptor also is expressed by cancer cell
subsets16 and that tumor cell-intrinsic PD1 pathway acti-
vation promotes cancer progression by triggering tumor
cell-intrinsic growth pathways, including PI3K/AKT/
mTOR.16–18
This study aimed to characterize PD1 expression pro-
files in tumor biospecimens obtained from patients with
resectable adenocarcinoma of the esophagogastric junction
(AEG) and to assess whether TIL and/or tumoral PD1
expression levels correlate with patient prognosis, includ-
ing disease-free survival, OS, and other clinicopathologic
parameters.
METHODS
Study Population
Consecutive patients from a prospective database who
had received esophageal resection for AEG between 1992
and 2011 in the Department of Surgery at the Medical
University of Vienna were included in this analysis.
Finally, 168 patients were identified, and data were col-
lected using the institutional database and review of
individual patients’ charts. The follow-up evaluation was
performed according to the institutional policy. All patients
were followed at 3-months interval during the first year
after esophagectomy, at 6-month intervals during the next
3 years after esophagectomy, and yearly thereafter. Tissue
samples of resected tumors were collected and used for
histologic analysis. The study was approved by the local
ethics committee of the Medical University of Vienna
(#1056/2016).
Immunohistochemistry (IHC)
For immunohistochemical analyses, 3- to 5-lm-thick
paraffin sections were used as previously described.19
Expression of PD1 was detected by using anti-human PD1
antibody (R&D Systems, #AF 1086, dilution 1:20). Anti-
gen retrieval was achieved by heating slides in a Dako
Cytomation Pascal Pressure Cooker, and 3% hydrogen
peroxide in distilled water was used to block the endoge-
nous peroxidase activity. Nonspecific epitopes were
blocked with normal goat serum (30 min), and the sections
then were incubated successively with primary antibody
(1:20 dilution, 60 min, room temperature) and corre-
sponding biotinylated anti-goat immunoglobulin G
secondary antibody (1:100 dilution, 30 min). According to
the manufacturer’s protocol (Dako), visualization via
streptavidin conjugated to alkaline phosphatase was
implemented. To depict the cell nuclei, additional Mayer’s
hematoxylin staining was applied.
For each slide, four different areas of esophageal ade-
nocarcinoma were selected for analysis. The
immunoreactivity for PD1 of tumor cells and lymphocytes
was examined at 9400 magnification, and the staining rate
(percentage of tumor cells and lymphocytes showing
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positive staining, 0–100%) was determined. Expression of
PD1 was categorized as 0 (no positive cells), 1 ? (5–25%
of cells), 2 ? (26–50% of cells), 3 ? (51–75% of cells),
and 4 ? (76–100% of cells). Three pathologists blinded to
the clinical characteristics of each patient evaluated the
staining for both tumor cells and lymphocytes and inde-
pendently graded each slide. If the rating differed, the slide
was re-discussed using a multi-head microscope, and a
consensus was found. The cutoff for positive PD1
expression was set at 5% based on the expertise of the
pathologists, which showed 5% as the cutoff to be practical
with the staining patterns, especially in terms of a future
clinical application. Additionally, previous publications on
PD1-L expression as a biomarker for treatment have
identified a cutoff of 5%.20–22
Statistical Analysis
Statistical analysis was performed with SPSS 20 (SPSS,
Inc., Chicago IL, USA). The association of PD1 expression
and clinicopathologic parameters was analyzed using the
Chi square test, t test, or Mann–Whitney U test. For the
calculation of OS, the time between primary surgery and
the patient’s death was analyzed. Disease-free survival
(DFS) was defined as the time from primary surgery until
the first evidence of disease progression. For the calcula-
tion of both OS and DFS, patients without complete
resection (n = 23) were excluded from the analyses. The
influence of PD1 expression on tumor cells and lympho-
cytes as well as the influence of other clinicopathologic
findings on OS and DFS was evaluated with the Kaplan–
Meier method, log-rank tests, and the Cox proportional
hazard model. All tests were performed in a two-sided
manner, and p values lower than 0.05 were considered to
be statistically significant.
RESULTS
Patients’ Characteristics
The study included 168 patients with esophageal ade-
nocarcinoma. The ratio of female to male patients was
31:137, and the mean age at surgery was 65 ± 10.4 years
(range 35–88 years). The median follow-up time was
29.4 months (range 0–196 months). The patients with
complete resection (n = 145) had a 1-year OS rate of
78.6% (107 of 145 patients at risk) a 5-year OS rate of
49.9% (54 of 145 patients at risk), and a 10- year OS rate of
37.3% (12 of 145 patients at risk). These patients had
1-year DFS rate of 72.6% (79 of 145 patients at risk), a
5-year DFS rate of 48.7% (31 of 145 patients at risk), and a
10-year DFS rate of 39.7% (6 of 145 patients at risk). Of
the 168 patients, 63 (37.5%) had received neoadjuvant
therapy (59 had neoadjuvant chemotherapy and 4 had
neoadjuvant radiochemotherapy). The clinical and
histopathologic data are summarized in Tables 1 and 2.
Expression of PD1 by TILs and by Tumor Cells
For each patient, histologic expression of PD1 was eval-
uated separately for TILs and tumor cells, with 136 (81%) of
the 168 of patients showing high PD1 expression ([5%) on
TILs (expression patterns: 0 [0%]: 19%; 1 ? [5–25%]: 33%;
2 ? [26–50%]: 40%; and 3 ? [51–75%]: 7%) (Table 1). In
130 (77%) of the patients, PD1 expression was detected on
tumor cells (expression patterns: 0 [0%]: 22.6%;
1? [5–25%]: 21%; 2? [26–50%]: 18%; 3? [51–75%]:
26%; and 4? [76–100%]: 13%) (Table 2). Figure 1 shows
representative images for (a) negative (0) PD1 staining on
lymphocytes, and (b) 2? and (c) 3? positive PD1 staining
on lymphocytes as well as (d) negative (0) PD1 staining on
tumor cells and (e), 2? and (f) 4 ? positive PD1 staining on
tumor cells.
Tumors Containing PD1? TILs Versus Tumors Without
TIL-PD1 Expression
Clinicopathologic findings were evaluated for tumors
containing PD1? TILs versus those without (\5%) PD1?
TILs (Table 1). The two groups differed significantly in
terms of tumor stage (p\ 0.001, Chi square test) and
lymph node status (p = 0.007, Chi square test). Of the
patients graded as pT3 (45.8%), 98.7% were positive for
PD1 expression by TILs. In contrast, only 36.4% of the
patients graded as pT1 a or b (19.6%) were positive for
PD1 expression by TILs. The TILs PD1 expression patterns
did not differ significantly between the patients who had
received neoadjuvant therapy before surgery (n = 63) and
those who had not received neoadjuvant therapy
(p = 0.223; Table 1).
Tumors Containing PD1? Cancer Cells Versus Tumors
Without Detectable Cancer Cell-PD1
In this study, PD1? tumor cells were significantly more
frequent in patients with advanced tumor stage (p\ 0.001,
Chi square test) and lymph node metastasis (p = 0.004)
(Table 2). Almost 95% (94.8%) of the patients with stage
pT3 tumors (n = 73) were cancer PD1?, compared with
only 27% who had stage pT1 a and b tumors (n = 9). No
significant difference in the frequency of PD1? tumor cells
could be found between the patients who received neoad-
juvant therapy and those who did not (p = 0.105; Table 2).
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Correlation of TILs PD1? and Cancer PD1? Tumors
With OS and DFS
In the univariate analyses, the patients with PD1?
([5%) cancer cells showed a significantly lower OS than
the patients in whom PD1 was not detectable on cancer
cells (respective 1-, 5-, and 10-year survival rates of 74.6,
43.5, and 33.9% vs. 91.1, 68.8, and 48.1%; log-rank 0.047;
Table 3). However, the PD1 status on TILs did not sig-
nificantly influence OS (respective 1-, 5-, and 10-year
survival rates of 75.4, 45.2, and 35.2% vs. 90, 65.9, and
45.2%; log-rank 0.132; Table 3). In terms of DFS, the
cancer PD1? and TIL PD1? patients both demonstrated a
significantly reduced DFS (5-year DFS of 71.3 vs. 41.6%;
log-rank 0.008 and 73.3 vs. 41.9%; log-rank 0.008,
respectively; Table 3).
Uni- and Multivariate Analyses of the Influence
of Clinicopathologic Parameters on OS and DFS
All the described clinicopathologic parameters (PD1
expression by TILs and tumor cells, pT, pN, grading, and
R0 resection) showed a significant risk for both OS and
DFS except for PD1 expression by TILs for OS (Table 3).
TABLE 1 Association of programmed cell death protein 1 (PD1) expression by tumor infiltrating lymphocytes (TILs) with clinicopathologic
parameters in 182 patients with esophageal adenocarcinoma
Factor Adenocarcinoma
(n = 168) n (%)
PD1? TILs
(n = 136) n (%)
PD1- TILs
(n = 32) n (%)
p value
Tumor stage
High-grade
dysplasia
4 (2.4) 1 (25) 3 (75) \0.001
pT1a 13 (7.7) 5 (38.5) 8 (61.5)
pT1b 20 (11.9) 7 (35) 13 (65)
pT2 49 (29.2) 45 (91.8) 4 (8.2)
pT3 77 (45.8) 76 (98.7) 1 (1.3)
pT4 5 (3) 2 (40) 3 (60)
Lymph node status
pNx 13 (7.7) 0.007
pN0 61 (36.3) 41 (67.2) 20 (32.8)
pN1 31 (18.5) 28 (90.3) 3 (9.7)
pN2 26 (15.5) 24 (92.3) 2 (7.7)
pN3 37 (22) 32 (86.5) 5 (13.5)
Histologic grading
G1 7 (4.2) 5 (71.4) 2 (28.6) 0.350
G2 74 (44) 57 (77) 17 (23)
G3 87 (51.8) 74 (85.1) 13 (14.9)
Neoadjuvant therapy
Yes 63 (37.5) 54 (85.7) 9 (14.3) 0.223
Total resection
Yes 145 (86.3) 115 (79.3) 30 (20.7) 0.174
No 23 (13.7) 21 (91.3) 2 (8.7)
Siewert classification
AEG 1 101 (60.1) 76 (75.2) 25 (24.8) 0.016
AEG 2 44 (26.2) 42 (95.5) 2 (4.5)
AEG 3 23 (13.7) 18 (78.3) 5 (21.7)
PD1 expression by TILs
0 (0%) 32 (19)
1? (5–25%) 56 (33.3)
2? (26–50%) 68 (40.5)
3? (51–75%) 12 (7.1)
4? (76–100%) 0
AEG adenocarcinoma of the esophagogastric junction
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However, when Cox regression analyses were performed,
only lymph node status proved to be an independent risk
factor for OS (hazard ratio [HR] 1.716; 95% confidence
interval [CI] 1.332–2.211). The risk factors for DFS proved
to be tumor status (HR 1.524; 95% CI 1.063–2.185) and
lymph node status (HR 1.938; 95% CI 1.458–2.575)
(Table 3).
DISCUSSION
This study evaluated the PD1 status of tumor cells and
TILs in a large cohort of patients with esophageal
adenocarcinoma. To our knowledge, this was one of the
first studies aimed at comprehensively characterizing PD1
expression of this tumor entity in the TME. We detected
PD1 expression on both TILs and cancer cells in esopha-
geal tumor biospecimens, paralleling findings in human
malignant melanoma.7,16,23 Consistent with immunohisto-
chemical studies of normal and malignant hematopoietic
and other tissues, PD1 immunoreactivity marked subsets of
predominantly small TILs and larger cancer cells that
exhibited both cell surface and cytoplasmic staining for
PD1, with TILs showing the strongest staining
intensity.16,23–26
TABLE 2 Association of programmed cell death protein 1 (PD1) expression by tumor cells with clinicopathologic parameters in 182 patients
with esophageal adenocarcinoma
Factor Adenocarcinoma (n = 168) n (%) PD1? cancer cells (n = 130) n (%) PD1- cancer cells (n = 38) n (%) p value
Tumor stage
High-grade dysplasia 4 (2.4) 1 (25) 3 (75) \0.001
pT1a 13 (7.7) 3 (23.1) 10 (76.9)
pT1b 20 (11.9) 6 (30) 14 (70)
pT2 49 (29.2) 45 (91.8) 4 (8.2)
pT3 77 (45.8) 73 (94.8) 4 (5.2)
pT4 5 (3) 2 (40) 3 (60)
Lymph node status
pNx 13 (7.7) 0.004
pN0 61 (36.3) 38 (62.3) 23 (37.7)
pN1 31 (18.5) 27 (87.1) 4 (12.9)
pN2 26 (15.5) 22 (84.6) 4 (15.4)
pN3 37 (22) 33 (89.2) 4 (10.8)
Histologic grading
G1 7 (4.2) 5 (71.4) 2 (28.6) 0.225
G2 74 (44) 53 (71.6) 21 (28.4)
G3 87 (51.8) 72 (82.8) 15 (17.2)
Neoadjuvant therapy
Yes 63 (37.5) 53 (84.1) 10 (15.9) 0.105
Total resection
Yes 145 (86.3) 111 (76.6) 34 (23.4) 0.519
No 23 (13.7) 19 (82.6) 4 (17.4)
Siewert classification
AEG 1 101 (60.1) 72 (71.3) 29 (28.7) 0.058
AEG 2 44 (26.2) 39 (88.6) 5 (11.4)
AEG 3 23 (13.7) 19 (82.6) 4 (17.4)
PD1 expression by tumor cells
0 (0%) 38 (22.6)
1? (5–25%) 36 (21.4)
2? (26–50%) 30 (17.9)
3? (51–75%) 43 (25.6)
4? (76–100%) 21 (12.5)
PD1 programmed cell death protein 1, AEG adenocarcinoma of the esophagogastric junction
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FIG. 1 Programmed cell death protein 1 (PD1) expression on tumor-
infiltrating lymphocytes (TILs) (a–c) and tumor cells (d–f) in
esophageal adenocarcinoma detected by immunohistochemistry.
a Negative PD1 staining of TILs. b 2? (26–50%) positive staining
of TILs. c 3? (51–75%) positive staining of TILs. d Negative
staining of tumor cells. e 2? (26–50%) positive staining of tumor
cells. f 4? (75–100%) positive staining of tumor cells. The
immunoreactivity for PD1 of tumor cells and TILs was examined
at 9400 magnification, and the staining rate (percentage of tumor
cells and lymphocytes showing positive staining, 0–100%) was
determined. Arrows indicate examples for a positive PD1 staining on
TILs (white arrow) and tumor cells (black arrow)
TABLE 3 Uni- and multivariate Cox regression analyses estimating the influence of clinicopathologic parameters on overall survival (OS) and
disease-free survival (DFS)
Factor Univariate p value Multivariate p value Relative risk 95% CI
OS
PD1 expression by TILs 0.132 0.973 1.020 0.320–3.248
PD1 expression by tumor cells 0.047 0.804 1.161 0.357–3.779
pT 0.001 0.113 1.262 0.946–1.684
pN \0.001 \0.001 1.716 1.332–2.211
Grading 0.004 0.523 1.169 0.724–1.887
DFS
PD1 expression by TILs 0.008 0.281 0.492 0.136–1.786
PD1 expression by tumor cells 0.008 0.348 1.820 0.521–6.352
pT \0.001 0.022 1.524 1.063–2.185
pN \0.001 \0.001 1.938 1.458–2.575
Grading 0.022 0.646 0.888 0.535–1.475
CI confidence interval, PD1 programmed cell death protein 1, TILs tumor infiltration lymphocytes
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Although PD1 expression often is restricted to small
subsets of TILs and cancer cells in melanoma,16,23 our
findings indicated that PD1? cell frequencies in esophageal
adenocarcinoma often exceed those in other cancers.
Together, these observations provide a rationale for
examining the therapeutic utility of PD1 inhibitors in
patients with esophageal carcinomas, particularly those
with high levels of detectable PD1 expression by TILs and
cancer cells within biopsies of tumor tissue.
Importantly, we found that the presence of both PD1?
TILs and PD1? cancer cells within the TME significantly
correlated with tumor recurrence. Furthermore, high levels
of cancer cell-expressed PD1 within patients’ tumor biop-
sies significantly correlated with decreased OS in our
patient cohort. Although these differences were not inde-
pendent in multivariate analyses, these findings identified
PD1 as a potential biomarker of tumor virulence in eso-
phageal carcinoma. Moreover, they support the possibility
that the PD1 pathway might also functionally promote
tumor virulence in esophageal carcinoma given its elevated
expression in late tumor stages and correlation with
adverse patient outcome.
Our results further suggest that esophageal carcinoma,
like melanoma, could exploit the PD1 pathway to promote
cancer progression both by dampening tumor-specific
immunity via engagement of TIL-expressed PD1 and by
triggering tumor cell-intrinsic growth signals via engage-
ment of cancer cell-expressed PD1. However, whether PD1
does indeed modulate the antitumor immune response and/
or function as a tumor cell-intrinsic growth receptor in this
malignancy requires future dedicated studies. In a separate
study,13 PD1 and PD-L1 expression were assessed previ-
ously in tumor biospecimens from 349 patients with
esophageal squamous cell carcinoma, and PD-L1 expres-
sion levels were found to correlate significantly with
favorable outcome, whereas PD1 expression within the
TME did not show any significant associations with clini-
copathologic parameters.13
The pathophysiology of esophageal squamous cell car-
cinoma differs from that of esophageal adenocarcinoma.
The latter is marked by a high somatic mutation rate,27
presumably because of frequent exposure to gastric fluids
and subsequent chronic inflammation. Because both a high
mutational burden and chronic inflammation have been
linked to PD1 receptor expression in patients with chronic
inflammatory liver diseases 28 as well as in patients with
other cancers, including non-small cell lung cancer
(NSCLC),29 we were especially interested in PD1 expres-
sion patterns in patients with esophageal adenocarcinoma.
To date, only one study has analyzed PD1 pathway
member expression in esophageal adenocarcinoma, with an
emphasis on assessing expression of the PD1 ligands PD-
L1 and PD-L2. This study, conducted by Derks et al.,30
investigated tissue microarrays containing esophageal
tumor tissue cores as well as benign tissue controls
obtained from 354 patients. The authors detected PD-L2
expression in tissues associated with Barrett’s esophagus
and reported a potential association of the inflammatory
environment in Barrett’s esophagus and PD1 ligand
expression.30 A potential limitation of this study was the
use of tissue microarrays instead of whole tissue slides,
especially because esophageal adenocarcinomas are highly
heterogeneous.31,32 Consequently, several important areas
of the tumor might have been missed with analyses limited
to microarray-based tissue cores. Furthermore, PD1
expression by cancer cells was not evaluated in the study
by Derks et al.,30 and areas lacking a T-cell infiltrate often
were excluded from the analysis.13
In our study, patients with esophageal adenocarcinoma
expressed PD1 on both TILs and tumor cells. Importantly,
these expression patterns correlated with the patients’
tumor stage and outcome. Several phase 3 trials demon-
strated improved OS for melanoma, NSCLC, and renal cell
carcinoma patients treated with PD1-blocking antibod-
ies,33–38 resulting in Food and Drug Administration (FDA)
approval of two PD1 inhibitors as second-line therapies for
patients with these malignancies.
Regarding gastroesophageal cancer, multiple studies
currently are focused on blocking the PD1 pathway.39–42
One of these studies is the recently started phase 3 clinical
trial with nivolumab treatment for patients with unre-
sectable advanced or recurrent gastric cancer, including
gastroesophageal junction cancer (ONO-4538-12).
In this study, we found that in our cohort of 168 eso-
phageal adenocarcinoma patients, 81% (n = 136) showed
PD1 expression by TILs and 77.4% (n = 130) demon-
strated PD1 expression by tumor cells. Given the broad
success of PD1 pathway blockade, our findings of PD1
expression in esophageal carcinoma provide a strong
rationale for evaluating the therapeutic utility of PD1
inhibitors in this group of patients. Clinical trials are
warranted in this regard. Besides diminishing the protective
effect of PD1 ligand expression on receptor activation on
immune cells and thus abrogating the antitumoral response,
tumor growth might also be reduced via direct inhibition of
PD1 on esophageal adenocarcinoma tumor cells
themselves.
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